Glut-1 expression and in situ CD1a/CD57 immunologic deficit in keratoacanthoma and squamous cell carcinoma of immunocompetent patients

Applied Immunohistochemistry and Molecular Morphology

Volumn 19, Issue 3, 2011, Pages 239-245

  Cabibi, Daniela ^a   Aragona, Francesco ^a,b   Guarnotta, Carla ^a   Rodolico, Vito ^a   Zerilli, Monica ^a   Belmonte, Beatrice ^a   Schillaci, Loredana ^a   Aragona, Federico ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Istituto di Anatomia ed Istologia Patologica di Palermo   (Italy)

Author keywords

CD1a; CD57; glut 1; keratoacanthoma; squamous cell carcinoma

Indexed keywords

CD20 ANTIBODY; CD3 ANTIGEN; CD4 ANTIGEN; CD57 ANTIGEN; CD8 ANTIGEN; GLUCOSE TRANSPORTER 1; T6 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; IMMUNOHISTOCHEMISTRY; KERATOACANTHOMA; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; ULTRAVIOLET RADIATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD1; ANTIGENS, CD57; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; EXCITATORY AMINO ACID TRANSPORTER 2; FEMALE; HUMANS; IMMUNITY; KERATOACANTHOMA; MALE; MIDDLE AGED; SKIN DISEASES; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79955053628     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181f7b2f0     Document Type: Article

References (42)

1. Rosai J. Skin. In: Rosai J, ed. Rosai and Ackerman's Surgical Pathology. 9th ed. Vol 1. Philadeiphia: Mosby; 2004:150-151.
2. Patterson JW, Wick MR. Nonmelanocytic tumors of the skin, AFIP atlas of tumor pathology, Series 4. Silver Spring, Maryland: Arp Press; 2006:42-44.
3. Karaa A, Khachemoune A. Keratoacanthoma: a tumor in search of a classification. Int J Dermatol. 2007;46:671-678. (Pubitemid 47046182)
4. Godbolt A, Sullivan J, Weedon D. Keratoacanthoma with perineural invasion: a report of 40 cases. Australas J Dermatol. 2001; 42:168-171. (Pubitemid 32721555)
5. Mukunyadzi P, Sanderson RD, Fan CY, et al. The level of syndecan-1 expression is a distinguishing feature in behavior between keratoacanthoma and invasive cutaneous squamous cell carcinoma. Mod Pathol. 2002;15:45-49. (Pubitemid 34081458)
6. Schwartz RA. Keratoacanthoma: a clinico-pathologic enigma. Dermatol Surg. 2004;30(2 Pt 2):326-333. (Pubitemid 38313991)
7. Sànchez YE, Pilar S, Requena L, et al. Solitary Keratoacanthoma: a self-healing proliferation that frequently becomes malignant. Am J Dermatopathol. 2000;22:305-310. (Pubitemid 30618611)
8. Fernandez-Flores A. Apoptotic markers in the differential diagnosis of keratoacanthoma versus squamous cell carcinoma. Histopathology. 2005;50:275-287.
9. Manstein CH, Frauenhoffer CJ, Besden JE. Keratoacanthoma: is it a real entity? Ann Plast Surg. 1998;40:469-472. (Pubitemid 28215516)
10. Hodak E, Jones RE, Ackerman AB. Solitary keratoacanthoma is a squamous-cell carcinoma. Three examples with metastases. Am J Dearmatopathol. 1993;15:332-342.
11. Beham A, Regauer S, Soyer HP, et al. Keratoacanthoma: a clinically distinct variant of well differentiated squamous cell carcinoma. Adv Anat Pathol. 1998; 5:269-280.
12. Cribier B, Asch P, Grosshans E. Differentiating squamous cell carcinoma from keratoacanthoma using histopathological criteria. Is it possible? A study of 296 cases. Dermatology. 1999; 199:208-212.
13. Ackerman AB. Squamous-cell carcinoma versus keratoacanthoma. J Dermatol Surg Oncol. 1982;8:418.
14. Reisser C, Eichhorn K, Herold-Mende C et al. Expression of facilitative glucose transport proteins during development of squamous cell carcinomas of the head and neck. Int J Cancer. 1999;80:194-198. (Pubitemid 29001721)
15. Yen TC, See LC, Lai CH, et al. 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med. 2004;45:22-29.
16. Kato H, Takita J, Miyazaki T, et al. Correlation of 18- Ffluorodeoxyglucose (FDG) accumulation with glucose transporter (Glut-1) expression in esophageal squamous cell carcinoma. Anticancer Res. 2003;23:3263-3272. (Pubitemid 36975422)
17. Fisher E, McCoy M, Wechsler H. Analysis of histopathological and electron microscopic determinants of keratoacanthoma and squamous cell carcinoma. Cancer. 1972;29:1387-1397.
18. Takeda H, Kondo S. Differences between squamous cell carcinoma and keratoacanthoma in angiotensin type-1 receptor expression. Am J Pathol. 2001;158:1633-1637. (Pubitemid 32422928)
19. Schwartz RA. Keratoacanthoma: a clinico-pathologic enigma. Dermatol Surg. 2004;30:326-333. (Pubitemid 38313991)
20. Slater M, Barden JA. Differentiating keratoacanthoma from squamous cell carcinoma by the use of apoptotic and cell adhesion markers. Histopathology. 2005;47:170-178. (Pubitemid 41113120)
21. Melendez ND, Smoller BR, Morgan M. VCAM (CD-106) and ICAM (CD-54) adhesion molecules distinguish keratoacanthomas from cutaneous squamous cell carcinomas. Mod Pathol. 2003;16: 8-13. (Pubitemid 36152680)
22. Kerschmann L, Mc Calmont TH, Le Boit PE. P53 oncoprotein expression and proliferation index in keratoacanthoma and squamous cell carcinoma. Arch Dermatol. 1994;130:181-186.
23. Cain CT, Niemann TH, Argenyi ZB. Keratoacanthoma versus squamous cell carcinoma. An immunohistochemical reappraisal of p53 protein and proliferating cell nuclear antigen expression in keratoacanthoma-like tumors. Am J Dermatopathol. 1995;17: 324-331.
24. Putti TC, Teh M, Lee YS. Biological behavior of keratoacanthoma and squamous cell carcinoma: telomerase activity and COX-2 as potential markers. Mod Pathol. 2004;17:468-475. (Pubitemid 41646603)
25. Skalova A, Michal M. Patterns of cell proliferation in actinic keratoacanthomas and squamous cell carcinomas of the skin. Immunohistochemical study using the MIB 1 antibody in formalin-fixed paraffin sections. Am J Dermatopathol. 1995;17:332-334.
26. Ho T, Horn T, Finzi E. Transforming growth factor alpha expression helps to distinguish keratoacanthomas from squamous cell carcinomas. Arch Dermatol. 1991;127:1167-1171.
27. Kaabipour E, Haupt HM, Stern JB, et al. P16 expression in keratoacanthomas and squamous cell carcinomas of the skin: an immunohistochemical study. Arch Pathol Lab Med. 2006;130:69-73. (Pubitemid 43077238)
28. Gallimore A, Godkin A. Regulatory T cells and tumour immunityobservations in mice and men. Immunology. 2007;123:157-163.
29. Tieben LM, Berkhout RJ, Smits HL, et al. Detection of epidermodysplasia verruciformis-like human papillomavirus types in malignant and premalignant skin lesions of renal transplant recipients. Br J Dermatol. 1994;131:226-230. (Pubitemid 24251496)
30. Shamanin V, zur Hausen H, Lavergne D, et al. Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients. J Natl Cancer Inst. 1996;88:802-811. (Pubitemid 26187389)
31. De Villiers EM, Lavergne D, McLaren K, et al. Prevailing papillomavirus types in non-melanoma carcinomas of the skin in renal allograft recipients. Int J Cancer. 1997;73:356-361. (Pubitemid 27508898)
32. Purdie KJ, Surentheran T, Sterling JC, et al. Human papillomavirus gene expression in cutaneous squamous cell carcinomas from immunosuppressed and immunocompetent individuals. J Invest Dermatol. 2005;125:98-107. (Pubitemid 40981430)
33. Cleaver JE, Crowley E. UV damage, DNA repair and skin cancerogenesis. Front Biosci. 2002;7:1024.
34. Duthie MS, Kimber I, Norval M. The effects of ultraviolet radiation on the human immune system. Br J Dermatol. 1999;140:995.
35. Beissert S, Schwartz T. Mechanism involved in UV light-induced immunosoppression. J Investing Dermatol Symp Proc. 1999;4:61.
36. Schwarz T. 25 years of UV-induced immunosuppression mediated by T-cells-From disregarded T-suppressor cells to highly respected regulatory T-cells. Photochem Photobiol. 2008;84:10-18. (Pubitemid 350265098)
37. Clemente CG, Mihm MC, Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996;77:1303-1310. (Pubitemid 26102328)
38. Uppaluri R, Dunn GP, Lewis JS Jr. Related articles, links focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. Cancer Immun. 2008;8:16.
39. Jass JR. Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol. 1986;39:585-589. (Pubitemid 16069660)
40. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960-1964. (Pubitemid 44498003)
41. De Melo MR Jr, Araújo Filho JL, Patu VJ, et al. Langerhans cells in cutaneous tumours: immunohistochemistry study using a computer image analysis system. J Mol Histol. 2006;37:321-325. (Pubitemid 44885238)
42. Taube JM, Nichols AD, Bornman LS, et al. Langerhans cell density and high-grade vulvar intraepithelial neoplasia in women with human immunodeficiency virus infection. J Cutan Pathol. 2007; 34:565-570. (Pubitemid 46920262)